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Abstract
Lapatinib is an oral, small-molecule, dual tyrosine kinase inhibitor of epidermal growth factor receptors (EGFR, or ErbB/Her)
in solid tumors. Little is known about the effect of lapatinib on leukemia. Using human chronic myelogenous leukemia
(CML) K562 cells as an experimental model, we found that lapatinib simultaneously induced morphological changes
resembling apoptosis, autophagy, and megakaryocytic differentiation. Lapatinib-induced apoptosis was accompanied by a
decrease in mitochondrial transmembrane potential and was attenuated by the pancaspase inhibitor z-VAD-fmk, indicating
a mitochondria-mediated and caspase-dependent pathway. Lapatinib-induced autophagic cell death was verified by LC3-II
conversion, and upregulation of Beclin-1. Further, autophagy inhibitor 3-methyladenine as well as autophagy-related
proteins Beclin-1 (ATG6), ATG7, and ATG5 shRNA knockdown rescued the cells from lapatinib-induced growth inhibition. A
moderate number of lapatinib-treated K562 cells exhibited features of megakaryocytic differentiation. In summary, lapatinib
inhibited viability and induced multiple cellular events including apoptosis, autophagic cell death, and megakaryocytic
differentiation in human CML K562 cells. This distinct activity of lapatinib against CML cells suggests potential for lapatinib
as a therapeutic agent for treatment of CML. Further validation of lapatinib activity in vivo is warranted.
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Introduction
Epidermal growth factor receptors (EGFR or ErbB/Her) belong
to the receptor tyrosine kinase superfamily. The EGFR subclass is
made up of four closely related members: EGFR/ErbB1/Her1,
ErbB2/Her2/Neu, ErbB3/Her3, ErbB4/Her4 [1,2,3]. Formation
of homodimers or heterodimers of ErbB receptors is triggered after
binding to EGF-related growth factors. Upon activation, auto-
phosphorylation of tyrosine residues within the cytoplasmic
domains of EGFR/ErbB receptors trigger intracellular signaling
pathways, such as the phosphatidylinosithol-3-kinase (PI3K)
pathway, the Shc- and/or Grb2-mediated mitogen-activated
protein kinase (MAPK)-ERK1/2 pathway(s), the protein kinase
C (PKC) pathway, and other pathways involved in proliferation
response.
Due to the pivotal roles of aberrant EGFR signaling pathways
in the development of different kinds of malignant human cancers,
the receptor tyrosine kinase superfamily is well-studied. Overex-
pression of ErbB2 is found in about 30% of breast cancer patients
and is correlated with poor prognosis [1,2,3,4]. Among the ErbB
receptors, ErbB2 lacks its own ligands; therefore, ErbB2 forms
heterodimers with EGFR, ErbB3 or ErbB4, or even with other
family members, such as Insulin-like growth factor-1 receptor
(IGF-1R) [5,6]. Findings such as these suggest that the ErbBs may
be good molecular targets for various malignancies, including
breast cancer.
Lapatinib (Tykerb or GW-572016, GlaxoSmithKline) is a small-
molecule, tyrosine kinase inhibitor which targets both ErbB1 and
ErbB2 [2,3]. Due to its specificity to EGFR family members,
applicability to oral administration, and seemingly few adverse
effects, lapatinib has received considerable attention and is
undergoing clinical trials for treatment of various solid tumors,
including breast, head and neck, vulva, colon, prostate, and
stomach [7,8,9,10,11,12,13]. Lapatinib shows promise as a
therapy in combination with capecitabine for patients with
Her2-overexpressing advanced or metastatic breast cancer that
fails to respond to anthracycline, taxane, and the anti-Her2
monoclonal antibody transtuzumab [2,3]. As yet, however, no
hematological malignancies have been included in laboratory or
clinical investigations of lapatinib.
To date, agents possessing cytotoxicity, targeted therapeutic
activity and differentiation-inducing capacity have proven most
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cancer [14]. Chronic myelogenous leukemia (CML) is a clonal
disease characterized by the presence of the Philadelphia
chromosome and resultant BCR-Abl gene fusion with constitu-
tively active tyrosine kinase in .90% of patients. CML cells
producing BCR-Abl fusion protein, such as the K562 cell line, are
important experimental models because they allow the assessment
of multiple cellular and molecular events simultaneously, including
various modes of cell death [15,16], differentiation toward the
erythroid/macrophage/megakaryocyte lineages [14,16,17,18,19,
20], and downegulation of BCR-Abl tyrosine kinase [21].
In recent years, molecular target-based cancer therapy has been
successfully applied to improve the efficacy and ameliorate the
adverse effects of several conventional chemotherapeutic drugs.
The pharmacological activities of novel targeted therapeutics may
not be limited to currently recognized targets. For example, the
EGFR inhibitor erlotinib overcame drug resistance [22], and
PKC412 induced megakaryocytic differentiation in K562 cells
[19]. In this study, we evaluated the effect of lapatinib on cell
death and differentiation, and investigated its mechanism of action
in human CML K562 cells. We found that lapatinib induced
multiple cellular events simultaneously including apoptosis,
autophagic cell death, and megakaryocytic differentiation in
human CML K562 cells. Apoptosis was likely induced by a
caspase-dependent pathway and autophagic cell death was likely
induced via an ATG6-dependent pathway.
Methods
Cell culture and drug treatments
CML-derived K562 and MEG-01, acute myeloblastic leuke-
mia (AML)-derived HL-60, and acute promyelocytic leukemic
NB4 cells were cultured in Roswell Park Memorial Institute
(RPMI) 1640 medium supplemented with 10% fetal bovine
serum (Gibco, Grand Island, NY), 100 IU/ml of penicillin,
100 mg/ml of streptomycin (Gibco), and 50-mM b-mercaptoeth-
anol. Fresh blood from healthy donors was used for isolation of
primary CD14
+ mononuclear cells (MNC) by Ficoll-Paque PLUS
density gradient (Amersham Biosciences, Sunnyvale, CA) and
positive selection using CD14 MicroBeads (MACS Miltenyi
Biotech, Auburn, CA) according to manufacturer’s instructions.
The use of human peripheral blood leukocytes to isolate
monocytes was approved by the institutional review board of
Mackay Memorial Hospital, Taipei, Taiwan. Both human
CD14
+ monocytes and mouse bone marrow cells isolated from
femur were cultured in RPMI 1640 medium supplemented with
10% serum. Lapatinib was dissolved in dimethyl sulfoxide
(DMSO, Sigma Chemical Company, St. Louis, MO) as a
1,000-fold stock solution. K562 cells were either left untreated, or
incubated with DMSO as vehicle control and various concen-
trations of lapatinib for 1–3 days as indicated. For 1.25- or 2.5-
mM 3-methyladenine (3-MA, Sigma) co-treatment experiments,
a 20-mM stock solution of 3-MA was made up in culture
medium. To test the role of caspases, K562 cells were treated
with lapatinib alone or co-treated with both lapatinib and 20 mM
of the pancaspase inhibitor z-VAD-fmk (R&D, Minneapolis,
MN), and dissolved in DMSO as a 1,000-fold stock solution. For
some experiments, 1-mM1 2 - O-Tetradecanoylphorbol 13-acetate
(TPA, Sigma) treatment was used as the positive control for
megakaryocytic differentiation of the K562 cells. For observation
of morphology, cells were treated with drugs for 3 days and then
attached on slides using cytospin apparatus (CytoSpin, Thermo
Fisher Scientific), stained with Liu’s stain according to the
manufacturer’s instructions and observed microscopically.
Growth inhibition analysis
To assess cell growth kinetics, viable cells were counted using
the trypan blue (Gibco) dye exclusion method. K562 cells were
treated and counted on days 1, 2, and 3. The viability of the cells
was also measured using the tetrazolium (MTT) assay (Sigma)
or 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay (Promega,
Madison, WI). For the MTT assay, 1-mg/mL MTT was added
to the culture medium and the cells were incubated at 37uCf o r
4 h, then an equal volume of acid isopropanol (0.04 M HCl in
isopropanol) was added to dissolve the MTT dye inside the
viable cells. The absorbance was measured at 570 nm using an
enzyme-linked immunosorbent assay reader. For some experi-
ments MTS viability assay was conducted according to the
manufacturer’s instructions. The optical density (OD) value of
control cells (DMSO vehicle treated) was designated as 100%
viability. IC50 values were calculated by GraphPad Prism 4
software (GraphPad Software, San Diego, CA) from MTT assay
data at day 3.
Detection of apoptotic or dead cells by flow cytometry
K562 cells arrested at the sub G1 phase (hypodiploid or with
DNA laddering) were detected using a cell-cycle detection assay in
which the cells were resuspended in propidium iodide (PI, Sigma)-
containing hypotonic buffer (0.1% sodium citrate, 0.1% Triton X-
100, and 5 mg/ml PI) as previously described [15,16]. The DNA
content of the cells was measured by flow cytometry (FACSCa-
libur, Becton Dickenson, Mountain View, CA), and the percent-
age of sub G1 cells was calculated using FlowJo software (Tree
Star, Ashland, OR). For the annexin V apoptosis assay, K562 cells
were collected and resuspended in binding buffer containing
annexin V-fluorescein isothiocyanate (FITC) (Clontech, Mountain
View, CA) and PI; The percentage of apoptotic cells was measured
by flow cytometry with FSC vs. SSC plot (gated on live cell
population) using FlowJo software (excluded cell debris with PI
staining). For detection of the mitochondrial transmembrane
potential of cells, 3,39-dihexyloxacarbocyanine iodide (DiOC6(3))
(Molecular Probes, Eugene, OR) was used and detected by flow
cytometry according to manufacturer’s instructions. For detection
of CD61
+ cells, cells were stained with FITC-conjugated CD61
antibody (BD Biosciences Pharmingen, San Diego, CA) and 7-
AAD viability staining to exclude dead cells, and then measured by
flow cytometry.
Western blot analysis
After treatment, cells were collected and dissolved in lysis buffer
(50-mM Tris-HCl [pH 7.4], 150-mM NaCl, 5-mM EDTA, and
10% glycerol) with protease inhibitors (Roche Biochemicals,
Indianapolis, IN). Cell lysates were then subjected to 10% sodium
dodecylsulfate-polyacrylamide gel electrophoresis, and immuno-
blotted with the following antibodies: actin (Sigma), LC3 (Abgent,
San Diego, CA), ATG7 (Santa Cruz Biochemicals, Santa Cruz,
CA), Beclin-1 (or ATG6) (Cell Signaling, Beverly, MA), and
ATG12 (Cell Signaling) for detection of ATG5-ATG12 conju-
gates.
RNA-mediated gene knockdown
A lentivirus-based short hairpin RNA (shRNA) expression system
(The RNAi Consortium [TRC]) was used to knock down gene
expression of ATG5, ATG7 and Beclin-1. Galactosidase beta 1
(LacZ), and red fluorescent protein (RFP) specific constructs were
used as non-targeting shRNA controls. We obtained all pLKO.1-
shRNA constructs from the National RNAi Core Facility,
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used: TRCN0000151963 (ATG5), TRCN0000007587 (ATG7),
TRCN0000033549 (Beclin-1, #1), TRCN0000033552 (Beclin-1,
#2), TRCN0000072237 (LacZ), and TRCN0000072216 (RFP).
Lentivirus productions and lentiviral spin infections were performed
according to protocols provided by TRC. After puromycin
selection, cells were treated with lapatinib and viability was assayed,
as described above.
Figure 1. Inhibition of leukemia cell proliferation by lapatinib. K562 CML cells were left untreated or were treated with 0.1% dimethyl
sulfoxide (DMSO, vehicle), DMSO with different doses of lapatinib (2.5, 5, or 10 mM), or 12-O-Tetradecanoylphorbol 13-acetate (TPA) 10 mM for 1 to 3
days as indicated. (A) Cell numbers for each treatment were counted using trypan-blue dye exclusion assay. (B) Relative numbers of viable cells were
detected using MTT assay. (C–F) Inhibition of cell proliferation by lapatinib in leukemia cell lines, but not in primary CD14
+ mononuclear or bone
marrow cells. 1610
5/ml CML MEG-01 (C), AML NB4 (D), HL-60 cells (E), K562, or 5610
5/ml human CD14
+ mononuclear and mouse bone marrow cells
(F) were untreated (unTx), treated with DMSO vehicle (0), or DMSO with different doses of lapatinib (mM) for 2 (C), 3 (D–E), or 1–3 days (F). The raw
data (B and F) or relative percentage of growth inhibition (C–E) were assessed and calculated using both trypan-blue dye exclusion and MTS assays
(C–E) or MTT assays (F) as indicated in each figure as described in (A–B). Optical density (OD) values from DMSO-treated control cells were used as a
standard (0% cell death), and the relative percentage of growth inhibition was calculated using the following method: [(mean OD values from DMSO-
treated cells – mean OD values from drug-treated cells)/mean OD values from DMSO-treated cells]6100. The data are expressed as the mean 6 SEM.
*P,0.05, **P,0.01, ***P,0.001 (t-test) between lapatinib-treated and DMSO control cells.
doi:10.1371/journal.pone.0029014.g001
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concentrations of lapatinib or TPA as indicated for 1–3 days. Cells were collected and resuspended in propidium iodide (PI)-containing hypotonic
buffer, and then the percentage of apoptotic cells with DNA ladders (hypodiploid cells) was analyzed by flow cytometry. The data are expressed as
means 6 SEMs. (B) K562 cells were left untreated or treated with lapatinib for 3 days; cells were then collected, resuspended in both AnnexinV and PI
containing buffer, and analyzed by flow cytometry. The percentages of PI(+)/annexin(+) or PI(2)/annexin(+) cells are indicated in each figure. (C)
Induction of both apoptotic and non-apoptotic cell death by lapatinib in K562 cells. After DMSO or 10 mM lapatinib treatment for 1–3 days for K562,
or 3 days for HL-60, cells were split into two tubes and resuspended in PI-containing phosphate buffered saline (upper panel in left figure, total dead
cells) or PI-containing hypotonic buffer (lower panel in left figure, apoptotic cells), respectively, for simultaneously detecting total dead cells without
intact plasma membranes or apoptotic cells as described in (A). The graph in the right panel represents the data as: the percentage of total dead cells
(empty bars) and the percentages of apoptotic cells (solid bars). After drug treatment for 3 days, HL-60 cells were attached on slides using cytospin
apparatus and observed after staining with Liu’s stain (right panel of 2C). (D) After DMSO, 2.5, 5 or 10 mM lapatinib treatment for 8 or 16 h, K562 cells
were stained with both PI and DiOC6(3). The mitochondrial transmembrane potential of the cells was analyzed by flow cytometry. *P,0.05, **P,0.01,
***P,0.001 (t-test) between treated and DMSO control cells.
doi:10.1371/journal.pone.0029014.g002
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Effects of lapatinib on viability and morphology of
human CML K562 cells
Cell viability was evaluated using trypan blue dye exclusion
assay. Lapatinib reduced the number of viable K562 cells in a
dose-and time-dependent manner (Fig. 1A). This inhibitory
activity was verified using an MTT assay which showed a half-
maximal inhibitory concentration (IC50) of 1.49 mM for lapatinib
in K562 cells (Fig. 1B). To compare this result with the effect of
lapatinib on other leukemia cell lines, CML-derived MEG-01, and
AML-derived HL-60 and NB4 cells were tested. A similar pattern
of cytotoxicity was noted in all the cell lines tested (Figs. 1C–1E).
In contrast, lapatinib was less toxic to normal, primary human
CD14
+ monocytes and mouse bone marrow cells (Fig. 1F).
Effect of lapatinib on apoptosis
Cell-cycle analysis of DNA hypodipolid sub G1 cell components
(Fig. 2A–2C) and flow cytometric analysis of externalized
phosphatidylserine (Fig. 2B) suggested that lapatinib induced
apoptosis in both K562 and HL-60 cells. After exposure for 16 h,
lapatinib reduced the mitochondrial transmembrane potential
prior to reduction of cell viability (Fig. 2D), indicating involvement
of the mitochondria-mediated apoptotic pathway. Lapatinib
reduced viability and induced distinct morphological alterations
in human CML K562 cells. Intriguingly, morphological observa-
tion revealed multiple morphological cellular events at the effective
concentration, including chromatin condensation, formation of
apoptotic bodies, extensive intra-cytoplasm vesicles, and multi-
nucleated giant cells (Fig. 3A). These changes resembled changes
in K562 cells treated with TPA, a drug known to induce K562
cells to differentiate towards the megakaryocytic lineage [16,20].
Co-treatment with the pancaspase inhibitor z-VAD-fmk partially
blocked lapatinib-induced inhibition of viability and apoptosis
induction, suggesting that lapatinib activates both caspase-
dependent and caspase-independent cell death pathways
(Figs. 3C and 3D). Interestingly, at conditions that reduced
viability more than 95%, fewer than 40% of the K562 cells were
positive for apoptosis (Fig. 2C), in contrast, 80% of HL-60 cells
were positive for apoptosis after lapatinib treatment (right panel of
Fig. 2C). The morphological features of lapatinib-treated HL-60
cells correlated with the high percentage of apoptotic cells. High
levels of dead cells were detected at days 1–3, indicating that the
reduction in K562 cell numbers after lapatinib treatment is not
due to growth arrest or induction of apoptosis at later time points.
This raises the possibility that other, non-apoptotic modes of cell
death might be induced by lapatinib in K562 cells.
Lapatinib induces autophagic cell death in K562 cells via
an ATG6-dependent pathway
Because lapatinib induced numerous small vesicles in the
cytoplasm of a large proportion of treated cells (Fig. 3A), we
investigated the conversion of microtubule-associated protein 1
light chain 3-I (LC3-I) to the phoshatidylethanolamine-conjugated
Figure 3. Induction of autophagy in lapatinib-treated K562 cells. (A) Induction of morphological changes by lapatinib in K562 cells. After
drug treatment for 3 days, cells were attached on slides using cytospin apparatus and observed microscopically after staining with Liu’s stain. Arrows
indicate cells with giant contours, characteristic of megakaryocytic differentiation. (B) Expression profiles of autophagic factors in lapatinib-treated
K562 cells. K562 cell lysates were prepared 3 days (for LC3) or as indicated (for Beclin-1) after DMSO, 5, or 10 mM lapatinib exposure, then, the
amounts of LC3, Beclin-1, and actin were examined by immunoblotting using antibodies against the respective proteins. LC3-II is an autophagic
marker. (C–E) Abrogation of lapatinib-induced sub G1, but not growth inhibition, by pancaspase inhibitor z-VAD-fmk. After K562 cells were treated
with lapatinib alone or lapatinib plus 20 mM z-VAD-fmk for 48 h, growth inhibition (C), percentage of sub G1 cells (D), or LC3I to LC3II conversion
(LC3I/II) (E) was assessed by MTS assay, flow cytometry, or immunoblotting as described in Fig. 2 or Fig. 3B. Increased LC3II formation is indicated by
arrows. *P,0.05, ***P,0.001 (t-test).
doi:10.1371/journal.pone.0029014.g003
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of the cells with lapatinib induced LC3-II formation in a dose-
dependent manner (Fig. 3B), similar to LC3-II induction patterns
in serum-starved K562 cells (data not shown). To investigate
whether lapatinib-induced autophagy caused cell death, the effect
of 3-methyladenine (3-MA), which inhibits the sequestration of the
autophagy process, was tested. Pretreatment of cells with 3-MA
attenuated the lapatinib-mediated reduction of viability (Fig. 4).
This suggested that lapatinib-induced autophagy is a mode of cell
death.
We further examined the expression level of Beclin-1 (ATG6
protein), the mammalian homolog of yeast autophagy protein
ATG8, by immunoblot. Lapatinib induced expression of Beclin-1
in K562 cells in a dose dependent manner (Fig. 3B). To elucidate
the role of Beclin-1 in the lapatinib-treated cells, we knocked down
expression of Beclin-1 and autophagy-related proteins ATG7 and
ATG5 after transduction with a shRNA expression lentivirus
system (Fig. 5). Specific knockdown of Beclin-1, ATG7, and ATG5
mRNA, but not the non-targeting shRNA, rescued the cells from
lapatinib-mediated cell death, indicating that lapatinib induced
autophagy via an ATG6-dependent pathway (Fig. 5).
To clarify the role of caspases in lapatinib-induced autophagy,
we co-treated K562 cells with pancaspase inhibitor z-VAD-fmk
and lapatinib. Under conditions optimized for attenuation of
lapatinib-induced apoptosis, z-VAD-fmk augmented the conver-
sion of LC3-I to LC3-II (Fig. 3E). These data suggest that the
autophagic cell death-induced by lapatinib could be caspase
independent in K562 cells. Thus, it is probable that lapatinib
induced autophagic cell death in K562 cells occurs via an ATG6-
dependent and caspase-independent pathway.
Effect of lapatinib on megakaryocytic differentiation
Some K562 cells were observed to exhibit giant contours, a
feature typical of megakaryocytes (Fig. 3A). To validate the
observed megakaryocytic differentiation, we used flow cytometry
to detect surface expression of CD61, a megakaryocytic marker
(Fig. 6). Lapatinib induced moderately upregulated expression of
CD61 (Figs. 3A and 6). TPA was used to verify the megakaryocytic
differentiation [23]. Differentiation toward the erythroid cell
lineage was excluded by lack of staining with benzidine in
lapatinib-treated K562 cells (data not shown).
Discussion
In this study we demonstrated that lapatinib induced myeloid
leukemia cell death in CML K562, MEG-01, AML HL-60 and
NB4 cells (Figs. 1A–1E) and showed much more toxicity than their
normal counterpart human CD14
+ monocytes, or mouse bone
marrow cells (Fig. 1F). The lack of cell growth in these two
primary cell populations, as indicated by the decrease cell number
in the untreated cells on day 2 and day 3 when compared to the
robust growth kinetics of K562 cells (Fig. 1F), possibly is caused by
differential sensitivity to lapatinib treatment on primary and
cancer cells. Lapatinib induced both apoptosis and autophagy
(Figs. 2, 3, 4, 5, and 6) in CML K562 cells, which correlated with
the induction of megakaryocytic differentiation of the cells. The
IC50 of lapatinib, as shown by MTT assay, was about 1.49 mM for
K562 cells (Fig. 1). The sensitivity to lapatinib varies among
different human cancer cell lines. For example, the IC50 ranged
from 0.01 to 18.6 mM for breast, 0.057 to 11.5 mM for lung, 0.029
to 3.074 mM for head and neck, and 1.51 to 7.7 mM for colon
cancer cell lines [10,12,24,25]. This implies that the therapeutic
window for each type of cancer needs to be determined in vivo
after screening anti-cancer activity using in vitro systems.
Some recent studies have focused on autophagy and necroptosis
as causes of programmed cell death [26,27]. The differentiating
features of these types of cell death in comparison with apoptosis
include massive autophagic vacuolization (double-membrane
vacuoles) inside the cytoplasm and the occurrence of cell death
in the absence of chromosome condensation and nuclear
fragmentation [16,28,29]. In our study, besides autophagic
vacuoles, specific features of autophagic cell death also included
conversion of LC-I to LC-II and involvement of autophagy-related
proteins and Beclin-1 (Figs. 3 and 5). In addition, induction of
autophagy by lapatinib in K562 cells included the protection of
cells from lapatinib-induced cell death by an autophagy inhibitor
and knockdown of autophagy-related proteins (Figs. 4 and 5).
Induction of autophagy marker LC3-II in lapatinib-treated K562
cells occurred in a dose dependent manner (Fig. 3B), similar to the
effect of lapatinib in HCT116 colon cancer cells [30]. Only a few
articles have discussed the induction of autophagy by lapatinib,
including one in which HCT116 colon cancer cells were used as
the model cell system [30]. LC3-I constitutive expression is a
relatively unique characteristic of K562 cells (Fig. 3) [31], which is
consistent with recent studies that have noted the constitutive
Figure 4. Rescue of K562 cells from lapatinib-induced cytotox-
icity by the autophagy inhibitor 3-methyladenine (3-MA). K562
cells were left untreated or were treated with various concentrations of
lapatinib in the presence or absence of 1.25-mM or 2.5-mM 3-MA for 24
(A) or 48 h (B) as indicated in each figure. Relative amounts of viable
cells were detected using the MTS assay, and the relative percentage of
growth inhibition was calculated as described in Fig. 1. *P,0.05,
**P,0.01 (t-test).
doi:10.1371/journal.pone.0029014.g004
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regardless of nutritional conditions [16,32,33]. Consistent with the
induction of autophagy by lapatinib, we found that the pancaspase
inhibitor z-VAD-fmk only weakly reduced growth inhibition by
lapatinib despite an effective blockage of apoptotic cell death
(Figs. 3C–3D). The autophagic marker LC3II was further
increased by z-VAD-fmk when K562 cells were treated with
5 mM lapatinib (Fig. 3E), suggesting more cells underwent
autophagy when the apoptotic pathway was blocked by z-VAD-
fmk [34]. Unlike results reported for U937 or L929 cells [35], we
did not find cytotoxicity with 20-mM z-VAD-fmk treatment alone
in K562 cells (Fig. 3C). We further found that autophagy
correlated with differentiation in K562 cells. This result is
consistent with a similar finding in TPA-treated K562 cells [20].
Necroptosis is necrosis-like programmed cell death that does not
include degradation and condensation of chromosomal DNA,
similar to autophagic cell death. Recent findings suggest that
receptor-interacting protein 3 (RIP3) switches TNF-induced death
to receptor-interacting protein 1 (RIP1)-related necroptosis [36].
Further experiments to explore the role of RIP1 in lapatinib-
induced cell death are ongoing.
We further found that lapatinib induced differentiation of K562
cells. Considerable evidence suggests that induction of cytotoxic
activity and differentiation occurs with other inhibitors of EGFR,
such as gefitinib and erlotinib, in both leukemia cell lines and
leukemia patients [37,38,39,40,41,42,43,44,45]. Interestingly, one
Figure 5. Protection of K562 cells from lapatinib-induced cytotoxicity by knockdown of autophagy-related proteins. After
transduction with shRNA expression lentivirus as indicated in each figure, K562 cells were selected and kept in puromycin-containing medium. Cells
were treated with DMSO or lapatinib for 72 (A) or 48 h (B), and then the relative percentages of growth inhibition were detected using the MTS assay
(A, left panel and B, upper panel) or trypan blue exclusion assay (A, right panel and B, lower panel) and calculated as described in Fig. 1. Knockdown
efficiency of ATG7, beclin-1, and ATG5-12 conjugates or the loading control, actin, were examined by immunoblotting using antibody against the
respective proteins as described in Fig. 3. *P,0.05, **P,0.01, ***P,0.001 (t-test).
doi:10.1371/journal.pone.0029014.g005
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myelogenous leukemia after treatment with erlotinib [46], which
resembled the application of all trans retinoic acid (ATRA) for
acute promyelocytic leukemia by changing the differentiation
status.
To the best of our knowledge, the evidence that lapatinib
induces three distinct cellular events is unique. The possible
action scenarios might be: (1) cells progress from one cellular
event to another, (2) three subpopulations of cells respond
differentially to lapatinib, or (3) a switch exists between each
event. Although a possible switch between apoptosis and
autophgy has been proposed (Fig. 3E and discussed in [47]), this
issue warrants further investigation. In addition, further exper-
iments are required to explore whether the mechanisms of
lapatinib-induced cell death in leukemia are different than the
mechanisms that kill cancer cell lines that die in much lower
concentrations, such as breast cancer cells with higher levels of
ErbB2 expression [10,12,24,25].
The potential targets of lapatinib or off-target effects of lapatinib
in leukemia need to be further elucidated, since there was no
evidence of expression of EGFR or ErbB2 in K562 cells [48,49]. A
few studies have reported the expression of ErbB receptor
members in a subset of lymphoid cells from patients with CML
or acute lymphoblastic leukemia [48,50,51]. Our preliminary
results and other studies have shown that ErbB2 transcripts, but
not EGFR transcripts, were detectable in leukemia cell lines other
than K562 (data not shown) [43,49]. Interestingly, in HL-60,
ErbB2 transcript was detectable, but ErbB2 protein was
undetectable [43]. The expression profiles of ErbB family
members and their correlations with lapatinib sensitivity remain
to be investigated. Along the same lines, ErbB2 and IGF-1R
heterodimers contributed to trastuzumab resistance in breast
cancer cells [5,6]. Additionally, the IGF-1R autocrine loop is an
important survival signal in leukemia [52], and IGF-1R signaling
synergistically amplifies Abl receptor tyrosine kinase aberrant
forms, one of the most common mutations in leukemia [53]. In an
effort to further dissect the mechanisms of the cytotoxic effects of
lapatinib in K562 cells, we attempted to investigate the kinetics of
BCR-Abl expression by Western blot; however, we found the
results to be complicated: both BCR-Abl expression and
phosphotyrosine of BCR-Abl were upregulated on day 1 but
downregulated on day 2 in lapatinib-treated K562 cells (data not
shown). Therefore, we will continue to study potential targets of
lapatinib in CML K562 cells.
Figure 6. Induction of megakaryocytic differentiation by lapatinib in K562 cells. (A) After 10-mM lapatinib or 1-mM TPA treatment, K562
cells were collected, stained with anti-CD61-FITC, and the fluorescent intensity of FITC in the live cells was analyzed. The percentage of CD61 positive
cells for each figure is indicated. (B) Data from separate experiments of drug exposure for 1–3 days in (A) are expressed as mean induction folds of
CD61 positive cells as follows: percentage of CD61 positive cells (lapatinib or TPA)/percentage of CD61 positive cells (DMSO). (C) Data from separate
experiments of lapatinib exposure for 1–3 days in (A) are expressed as percentage induction of mean fluorescence as follows: [mean fluorescence
(lapatinib or TPA)/mean fluorescence (DMSO)]6100. *P,0.05 (t-test).
doi:10.1371/journal.pone.0029014.g006
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PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e29014In conclusion, we demonstrated induction of autophagy,
apoptosis, and differentiation of K562 cells upon lapatinib
treatment. Apoptosis was likely induced by a caspase-dependent
pathway and autophagic cell death was likely induced via an
ATG6-dependent pathway. These findings suggest that lapatinib
may have potential for the treatment of leukemia.
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